Literature DB >> 24671693

The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.

Joshua O Marshak1, Lichun Dong, David M Koelle.   

Abstract

DNA vaccines have been licensed in veterinary medicine and have promise for humans. This format is relatively immunogenic in mice and guinea pigs, the two principle HSV-2 animal models, permitting rapid assessment of vectors, antigens, adjuvants, and delivery systems. Limitations include the relatively poor immunogenicity of naked DNA in humans and the profound differences in HSV-2 pathogenesis between host species. Herein, we detail lessons learned over the last few years investigating candidate DNA vaccines in the progesterone-primed female mouse vaginal model of HSV-2 infection as a guide to investigators in the field.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24671693      PMCID： PMC4084910          DOI： 10.1007/978-1-4939-0428-0_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  33 in total

1.  Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa.

Authors:  Amalia S Magaret; Anna Wald; Meei-Li Huang; Stacy Selke; Larry Corey
Journal:  J Clin Microbiol       Date:  2007-02-28       Impact factor: 5.948

2.  Different patterns of peripheral migration by memory CD4+ and CD8+ T cells.

Authors:  Thomas Gebhardt; Paul G Whitney; Ali Zaid; Laura K Mackay; Andrew G Brooks; William R Heath; Francis R Carbone; Scott N Mueller
Journal:  Nature       Date:  2011-08-14       Impact factor: 49.962

3.  Thymidine kinase-deficient herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  L R Stanberry; S Kit; M G Myers
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

4.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

5.  Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.

Authors:  Mark Shlapobersky; Joshua O Marshak; Lichun Dong; Meei-Li Huang; Qun Wei; Alice Chu; Alain Rolland; Sean Sullivan; David M Koelle
Journal:  J Gen Virol       Date:  2012-03-07       Impact factor: 3.891

6.  A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Authors:  William P Halford; Ringo Püschel; Edward Gershburg; Andrew Wilber; Svetlana Gershburg; Brandon Rakowski
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

7.  Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections.

Authors:  Michael L Freeman; Brian S Sheridan; Robert H Bonneau; Robert L Hendricks
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

9.  Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation.

Authors:  Thomas L Cherpes; James L Busch; Brian S Sheridan; Stephen A K Harvey; Robert L Hendricks
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

10.  CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help.

Authors:  Yusuke Nakanishi; Bao Lu; Craig Gerard; Akiko Iwasaki
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962
View more
  4 in total

Review 1.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

2.  Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.

Authors:  Nicolas Çuburu; Kening Wang; Kyle N Goodman; Yuk Ying Pang; Cynthia D Thompson; Douglas R Lowy; Jeffrey I Cohen; John T Schiller
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

3.  Il4ra-independent vaginal eosinophil accumulation following helminth infection exacerbates epithelial ulcerative pathology of HSV-2 infection.

Authors:  Alisha Chetty; Matthew G Darby; Pia M Vornewald; Mara Martín-Alonso; Anna Filz; Manuel Ritter; Henry J McSorley; Lindi Masson; Katherine Smith; Frank Brombacher; Matthew K O'Shea; Adam F Cunningham; Bernhard Ryffel; Menno J Oudhoff; Benjamin G Dewals; Laura E Layland; William G C Horsnell
Journal:  Cell Host Microbe       Date:  2021-04-14       Impact factor: 21.023

4.  CCL28 Enhances HSV-2 gB-Specific Th1-Polarized Immune Responses against Lethal Vaginal Challenge in Mice.

Authors:  Yan Yan; Kai Hu; Ming Fu; Xu Deng; Xinmeng Guan; Sukun Luo; Mudan Zhang; Yalan Liu; Qinxue Hu
Journal:  Vaccines (Basel)       Date:  2022-08-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.